Term
dx disease: myeloperoxidase+, CD13+, CD33+, CD34+ |
|
Definition
|
|
Term
dx disease: Sudan Black+, CD14+, CD68+ |
|
Definition
|
|
Term
stage of B cell development: TdT+, CD34+ (CD19/22/10/cyto mu -) |
|
Definition
|
|
Term
stage of B cell development: TdT+, CD34+, CD19+, CD22+, CD10+ (CD20-, cyto mu-) |
|
Definition
|
|
Term
stage of B cell development: TdT+, CD34-, CD19/22/10+, CD20+, cyto mu+ |
|
Definition
|
|
Term
stage of B cell development: TdT-, CD34-, CD19/22+, CD10+, CD20+, CD21+, cyto mu- |
|
Definition
|
|
Term
stage of T cell development: CD7, CD2, CD5, CD1, CD4/8 |
|
Definition
|
|
Term
stage of T cell development: CD4/8, TCR, CD3 |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
good prognostic factors for ALL (5) |
|
Definition
pro-B phenotype, hyperdiploidy, t(12:21), 2-10yo, <100,000 WBC/ul |
|
|
Term
poor prognostic factors for ALL (5) |
|
Definition
pre-T or pre-B phenotype, hypodiploidy, t(9:22), <2yo or adult/adolescence, >100,000 WBC/ul |
|
|
Term
|
Definition
|
|
Term
dx disease: TdT, CD34+, CD10+, CD19(pro)/CD20(pre), IgM |
|
Definition
|
|
Term
Burkitt lymphoma cell markers |
|
Definition
|
|
Term
dx disease: t(8:14), t(2:8), t(8:22) |
|
Definition
|
|
Term
Burkitt lymphoma translocations (3) |
|
Definition
|
|
Term
|
Definition
c-myc/Ig heavy chain; Burkitt's |
|
|
Term
|
Definition
kappa light chain/c-myc; Burkitt's |
|
|
Term
|
Definition
c-myc/lambda light chain; Burkitt's |
|
|
Term
follicular lymphoma cell markers |
|
Definition
|
|
Term
follicular lymphoma translocation |
|
Definition
|
|
Term
|
Definition
follicular lymphoma or marginal zone lymphoma depending on what is translocated on chrom 18; if Bcl-2 -> follicular; if MALT1 -> marginal |
|
|
Term
|
Definition
|
|
Term
|
Definition
Ig heavy chain/Bcl-2; follicular lymphoma |
|
|
Term
dx leukemia: CD19, CD20, CD5+, Ig+ |
|
Definition
chronic lymphocytic leukemia |
|
|
Term
dx lymphoma: CD19, CD20, CD5+, Ig+, cyclin D1++ |
|
Definition
|
|
Term
dx disease: smudge cells in peripheral blood smear |
|
Definition
|
|
Term
AML is more common in ___; ALL is more common in ___. |
|
Definition
AML is more common in adults; ALL is more common in children. |
|
|
Term
|
Definition
miRNA15/16 deletion, which targets Bcl-2 for degradation |
|
|
Term
dx disease: 13q14.3 deletion |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
dx disease: t(11:18), t(14:18), or t(1:14) |
|
Definition
|
|
Term
complication of Hashimoto's thyroiditis, Sjogren's in salivary glands, H. pylori stomach infection |
|
Definition
|
|
Term
MALT or Bcl-10 overexpression |
|
Definition
|
|
Term
dx disease: CD19/20, Ig+, Bcl-6 mutation |
|
Definition
diffuse large B cell lymphoma |
|
|
Term
complication of KSHV infection seen in AIDS pts |
|
Definition
primary effusion DLBCL, no associated mass, in ascitic or pleural cavities |
|
|
Term
16yo presents with enlarged mediastinal mass; upon biopsy, it is hypercellular with bands of fibrosis; dx? |
|
Definition
T cell acute lymphoblastic leukemia |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
pt presents with plaque of epidermis; biopsy shows Pautrier's abscesses; dx? |
|
Definition
|
|
Term
pt presents with exfoliate erythroderma; peripheral blood smear shows cerebriform nuclei |
|
Definition
|
|
Term
|
Definition
anaplastic large cell syndrome |
|
|
Term
|
Definition
|
|
Term
|
Definition
anaplastic large cell syndrome |
|
|
Term
|
Definition
|
|
Term
CD19-, CD20-, CD15+, CD30+; dx? |
|
Definition
|
|
Term
|
Definition
Nodular lymphocyte predominent Hodgkin's lymphoma |
|
|
Term
CD19+, CD20+, CD15-, CD30-; dx? |
|
Definition
Nodular lymphocyte predominant Hodgkin's lymphoma |
|
|
Term
|
Definition
Nodular lymphocyte predominent Hodgkin's lymphoma |
|
|
Term
marginal zone lymphoma translocations |
|
Definition
t(11;18), t(14;18), t(1;14) |
|
|
Term
50yo African American male complains of back and hip pain that is worse at night; history of multiple fractures; radiographs show punched-out lesions; dx? |
|
Definition
|
|
Term
what are the major criteria for a multiple myeloma dx? |
|
Definition
>30% myeloblasts in bone marrow, serum or urine M spike, plasmacytoma |
|
|
Term
what are the minor criteria for multiple myeloma dx? |
|
Definition
>10% myeloblasts in bone marrow, lytic bone lesions, reduced normal Igs |
|
|
Term
what are the 5 ways multiple myeloma causes renal disease? |
|
Definition
renal casts, amyloid deposits/light chain deposits, plasma cell infiltration, distal tubule acidosis, end stage renal disease |
|
|
Term
tx for neurological defects associated with multiple myeloma |
|
Definition
steroids, radiation therapy |
|
|
Term
hyperviscosity syndrome is caused by which immunoglobulins? |
|
Definition
|
|
Term
poor prognostic indicators for multiple myeloma |
|
Definition
elevated serum beta-2 microglobulin, LDH, CSR; hypodiploidy; increased angiogenesis |
|
|
Term
|
Definition
lenalidomide, thalizomide, bortezomib (and melphalan) |
|
|
Term
cytogenetics that cause multiple myeloma |
|
Definition
chromosome 14 translocation, del(13q) = Rb, del(17p) = p53 |
|
|
Term
what cytokines support multiple myeloma growth? |
|
Definition
|
|
Term
what cells produce IL-6? what cells produce VEGF? |
|
Definition
stromal cells produce IL-6; osteoclasts produce VEGF; malignant cells produce both |
|
|
Term
MOA of thalidomide and lenalidomide? (4) |
|
Definition
attack bone marrow niche, inhibit cytokine production, inhibit cell adhesion, upregulate Th1 and CTL response |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
dx: adult T cell leukemia |
|
|
Term
|
Definition
|
|
Term
|
Definition
dx: Hodgkin's lymphoma, classical, mixed cellularity |
|
|
Term
|
Definition
dx: nodular lymphocyte predominant Hodgkin's lymphoma |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
marginal zone lymphoma or follicular zone lymphoma |
|
|
Term
general tx regimen for ALL |
|
Definition
"ALL men want VAG"
vinblastine, asparaginase, glucocorticoid |
|
|
Term
|
Definition
anthracycline, alkylating agents, mitotic inhibitor (Braverman) |
|
|